Abstract
Background and methods. Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p 170) by immunocytochemistty (APAAP) with the MRK-16 monoclonal antibody. Results and conclusions. Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 ± 29.9) than in chronic phase (mean 3 ± 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDB may contribute significantly to treatment failure.
| Original language | English |
|---|---|
| Pages (from-to) | 200-204 |
| Number of pages | 5 |
| Journal | Haematologica |
| Volume | 79 |
| Issue number | 3 |
| Publication status | Published - 1994 |
Fingerprint
Keywords
- chemotherapy
- chronic myeloid leukemia
- drug resistance
ASJC Scopus subject areas
- Hematology
Cite this
Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. / Michelutti, A.; Michieli, M.; Damiani, D.; Melli, C.; Geromin, A.; Russo, D.; Fanin, R.; Baccarani, M.
In: Haematologica, Vol. 79, No. 3, 1994, p. 200-204.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia
AU - Michelutti, A.
AU - Michieli, M.
AU - Damiani, D.
AU - Melli, C.
AU - Geromin, A.
AU - Russo, D.
AU - Fanin, R.
AU - Baccarani, M.
PY - 1994
Y1 - 1994
N2 - Background and methods. Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p 170) by immunocytochemistty (APAAP) with the MRK-16 monoclonal antibody. Results and conclusions. Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 ± 29.9) than in chronic phase (mean 3 ± 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDB may contribute significantly to treatment failure.
AB - Background and methods. Philadelphia (Ph) positive chronic myeloid leukemia (CML) cannot be induced into a true remission with conventional chemotherapy. Blast cells and precursors obtained from 51 Ph+ CML cases were assayed for expression of the multidrug resistance (MDR)-associated glycoprotein (p 170) by immunocytochemistty (APAAP) with the MRK-16 monoclonal antibody. Results and conclusions. Positive cells were found in 11/17 cases in chronic phase (65%), in 4/8 cases in accelerated phase, and in 23/26 cases in blastic phase (89%). The proportion of positive cells, which ranged between less than 1% and 95%, was higher in blastic phase (mean 32 ± 29.9) than in chronic phase (mean 3 ± 5.3) (p = 0.006). These findings show that p170 overexpression is common in Ph+ CML, especially after progression to blastic phase, and suggest that p170-related MDB may contribute significantly to treatment failure.
KW - chemotherapy
KW - chronic myeloid leukemia
KW - drug resistance
UR - http://www.scopus.com/inward/record.url?scp=0027935266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027935266&partnerID=8YFLogxK
M3 - Article
C2 - 7926967
AN - SCOPUS:0027935266
VL - 79
SP - 200
EP - 204
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 3
ER -